The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global clinical microbiology market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Clinical microbiology is a field of medical science that assists in diagnosing, preventing, and treating various infectious diseases. It focuses on identifying the presence of bacterial, viral, fungal, or parasitic agents and determining the susceptibility of microorganisms by conducting various tests. Some of the commonly used testing methods are direct smears and stains, cultures, molecular analysis, serological testing, and antibiotic susceptibility testing. Presently, clinical microbiology is gaining traction across the globe on account of its effective antibiotic administration and improved treatment outcomes.
The increasing prevalence of infectious diseases around the world represents one of the primary factors propelling the growth of the market. Additionally, the rising air and water pollution levels are increasing incidences of respiratory diseases among individuals, which, in turn, is driving the market. Apart from this, the integration of automation in clinical microbiology is creating a favorable outlook for market growth as it enables specimen traceability, eliminates delays in incubations and improves the efficiency of laboratory operations. Furthermore, the leading players are focusing on introducing technological advancements in disease diagnostics, such as the adoption of machine learning (ML), which aids in providing quick and accurate results. This, along with the introduction of several molecular diagnostic techniques, is offering lucrative growth opportunities to the market. Moreover, the rising adoption of advanced clinical diagnostic techniques, including real-time polymerase chain reaction (PCR), next-generation sequencing (NGS), and mass spectrometry for effective identification and characterization of pathogens, is acting as another growth-inducing factor. Other major factors, including the increasing number of new microorganisms causing various infectious diseases and the burgeoning healthcare sector across the globe, are anticipated to impel the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global clinical microbiology market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc, Bruker Corporation, Danaher Corporation, Hologic Inc., Merck KGaA, QIAGEN N.V and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||3M Company, Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc, Bruker Corporation, Danaher Corporation, Hologic Inc., Merck KGaA, QIAGEN N.V and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
We expect the global clinical microbiology market to exhibit a CAGR of around 7% during 2021-2026.
The high prevalence of numerous infectious diseases, along with the rising investments in extensive R&D activities are primarily driving the global clinical microbiology market.
The sudden outbreak of the COVID-19 pandemic has led to the increasing adoption of clinical microbiology for testing fungal infections as a side-effect of coronavirus disease, thereby catalyzing the overall market growth.
Based on the product, the global clinical microbiology market can be segmented into laboratory instruments, automated culture systems, and reagents. Currently, laboratory instruments hold the majority of the total market share.
Based on the application, the global clinical microbiology market has been divided into respiratory diseases, bloodstream infections, gastrointestinal diseases, sexually transmitted diseases, urinary tract infections (UTIs), periodontal diseases, and others, where respiratory diseases exhibit a clear dominance in the market.
Based on the end user, the global clinical microbiology market can be categorized into hospitals and diagnostic centers, custom lab service providers, and academic and research institutes. Among these, hospitals and diagnostic centers account for the largest market share.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global clinical microbiology market include 3M Company, Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc, Bruker Corporation, Danaher Corporation, Hologic Inc., Merck KGaA, QIAGEN N.V, and Thermo Fisher Scientific Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at